PERINATOLOGY AND PEDIATRIC. UKRAINE. 2017.3(71):93-96; doi 10.15574/PP.2017.71.93

Oniskova O. V., Yushchenko L. O., Zalewska I. V.
Vinnytsya National Pyrogov Memorial Medical University, Ukraine

Results of investigation of neurotransmitter pathways, practical approaches to the antiemetic use and frequency of side effects are present in the article. The study evaluated the prevalence of extrapyramidal disorders which may be possible in case of using antiemetics. Understanding of neurotransmitter pathways, physicians awareness about neurological disorders which may be possible in case of using antiemetics help clinicians to improve the effectiveness of treatment of different diseases with nausea and vomiting, it makes treatment safeness and cost-effectiveness.
Key words: antiemetics, metoclopramide, adverse effects, extrapyramidal reactions.

References

1. Khenderson DzhM. (2005). Pathophysiology of the digestive system. Per s angl. Moskow, OOO «BINORM-Press», Kharkov, OOO «MTK-Kniga», 3-e izd, ispr: 272.

2. Shul'perkova YuO, Ivashkin VT. (2001). Nausea and vomiting in gastroenterological practice. RMZh BOP. 3; 1: 28-30

3. Jo YY, Kim YB, Yang MR, Chang YJ. (2012). Extrapyramidal side effects after metoclopramide administration in a post-anesthesia care unit. Korean J Anesthesiology. 63; 3: 274-276. https://doi.org/10.4097/kjae.2012.63.3.274; PMid:23060988 PMCid:PMC3460160

4. Flake ZA, Linn BS, Hornecker JR. (2015). Practical selection of antiemetics in the ambulatory setting. American Family Physician. 91; 5: 293-296. PMid:25822385

5. Moos DD, Hansen DJ. (2008). Metoclopramide and extrapyramidal symptoms: a case report. J Perianesth Nurs. 23; 5: 292-299. https://doi.org/10.1016/j.jopan.2008.07.006; PMid:18926476

6. Yaman A, Kendirli T. (2014). Neuroleptic malignant syndrome associated with metoclopramide in a child. Turk J Pediatr. 56; 5: 535-537. PMid:26022591

7. Wittmann O, Sadot E, Bisker-Kassif O et al. (2016). Neuroleptic Malignant Syndrome Associated With Metoclopramide Use in a Boy: Case Report and Review of the Literature. Am J Ther. 23; 5: 1246-1249. https://doi.org/10.1097/MJT.0000000000000320; PMid:26241559

8. Weinstein RB, Fife D, Sloan S et al. (2015). Prevalence of chronic metoclopramide use and associated diagnoses in the US pediatric population. Pediatr Drags. 17; 4: 331-337. https://doi.org/10.1007/s40272-015-0136-2; PMid:26014368 PMCid:PMC4516863

9. Mt-Isa S, Tomlin S, Sutcliffe A et al. (2015). Prokinetics prescribing in paediatrics: evidence on cisapride, domperidone, and metoclopramide. J Pediatr Gastroenterol Nutr. 60; 4: 508-514. https://doi.org/10.1097/MPG.0000000000000657; PMid:25825854

10. Cavero-Redondo I, Pozuelo-Carrascosa DP. (2015). Risk of extrapyramidal side effects comparing continuous vs. bolus intravenous metoclopramide administration: a systematic review and meta-analysis of randomised controlled trials. 24; 23-24: 3638-3646.

11. Lau Moon Lin M, Robinson PD, Flank J et al. (2016). The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. Drug Saf. 39; 7: 675-687. https://doi.org/10.1007/s40264-016-0418-9; PMid:27003816